News and insights
223 81 Lund, Sverige
+46 46-15 21 00
A tumor in the brain means major challenges – for the patient and for healthcare. In addition, it may be poorly localized making surgery difficult. Passing various nerve centers that control important functions of the body is critical. Supplementary treatment with chemotherapy and radiation is generally needed.
When using laser ablation in neurosurgery, so called laser interstitial thermal therapy (LITT), a region of interest is directly targeted and treated with high precision. Areas in the brain, not accessible for open surgery, can be treated as LITT is typically minially invasive through use of MRI guidance (MRgLITT), and a stereotactic access system.
In collaboration with partners and through clinical programs, CLS is expanding into MRgLITT for treatment of patients with tumors and other lesions in the brain, including epileptogenic foci.
A system for MR guided laser ablation in neurosurgery is cleared by the US Food and Drug Administration (FDA) as of September 22, 2022. It is commercialized by our partner ClearPoint Neuro Inc. under the brand name ClearPoint Prism™ Neuro Laser Therapy System, starting in the USA.
The new system includes CLS’s:
A clinical study at Skåne University Hospital, Lund , evaluating safety and feasibility using CLS new system for MRgLITT in minimally invasive ablation of lesions in the brain, such as primary tumors of patients diagnosed with glioblastoma, is now recruiting patients.
Glioblastoma is the most aggressive brain tumor and almost incurable. Despite intensive research and drug development the treatment of this disease remains a challenge. Hence, the need for new treatment options to offer affected patients is huge.
Our goal is to develop the field of therapy – by offering tools for precise and cost-efficient treatment.
Dan J. Mogren
26 September, 2022
We are proud to announce that CLS has received FDA 510(k) clearance for our MR guided laser ablation system in neurosurgery!
15 September, 2022
The first patient will shortly be treated with the CLS laser ablation system in a sponsored study at Skåne University Hospital. The Swedish medical journal Läkartidningen now reports from the hospital.
7 September, 2022
We are now in the final preparations for the Imperial Prostate Masterclass meeting in London taking place this week. This is a small meeting, but this is also where we well meet the leading specialists and KOLs in the field.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region